Affiliations: Department of Medical Oncology, Medicalpark Gaziantep Hospital, Gaziantep, Turkey
Correspondence:
[*]
Corresponding author: Mustafa Yıldırım, Department of Medical Oncology, Medicalpark Gaziantep Hospital, Mücahitler mh. 52063 sk. No: 2 Tehitkamil, 27090 Gaziantep, Turkey. Tel.: +90 533 3948252; Fax: +90 342 3248860; E-mail:mustafayildirim7@yahoo.com
Abstract: RCC constitutes approximately 90% of all renal malignancies and 2-3% of all malignant tumours in adults. In spite of the improvement in radiologic methods, nearly 30% of the early metastatic RCC patients are incidentally diagnosed. HMGB1 is an extracellular signalling molecule that plays a role both in inflammation and carcinogenesis. Patients who were followed in Medical Oncology Departments of Denizli Government Hospital and Antalya Education and Research Hospital with a histopathological diagnosis of RCC between years 2010-2012 were enrolled in this study. HMGB1 levels were also assessed in a manually performed quantitative sandwich-enzyme-linked immunosorbent assay (ELISA) assay kit. In our study, we showed that the serum level of HMGB1, whether 149.9 pg/ml or not is important in differential diagnosis between patient and control group.
Keywords: Renal cell cancer, diagnosis, high mobility group box (HMGB) proteins, Elisa
